Relmada Therapeutics (RLMD) Share-based Compensation (2014 - 2026)

Relmada Therapeutics (RLMD) has reported Share-based Compensation for 13 consecutive years, with $956186.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation fell 73.24% year-over-year to $956186.0; the TTM figure through Mar 2026 stood at $10.3 million (down 59.36% YoY), while the FY2025 annual figure was $13.9 million, down 53.93% from the prior year.
• Share-based Compensation eased to $956186.0 in Q1 2026 per RLMD's latest filing, from $2.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $12.3 million in Q2 2022 and bottomed at $956186.0 in Q1 2026.
• Historically, Share-based Compensation has averaged $8.0 million across 5 years, with a median of $8.3 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation surged 103.9% — and 2026, when it sank 73.24%.
• Relmada Therapeutics' Share-based Compensation stood at $11.6 million in 2022, then decreased by 14.9% to $9.9 million in 2023, then plunged by 32.02% to $6.7 million in 2024, then sank by 64.75% to $2.4 million in 2025, then plunged by 59.67% to $956186.0 in 2026.
• Business Quant data shows RLMD's Share-based Compensation at $956186.0 in Q1 2026, $2.4 million in Q4 2025, and $7.7 million in Q3 2025.